3627 related articles for article (PubMed ID: 22646630)
1. Preoperative chemoradiotherapy for esophageal or junctional cancer.
van Hagen P; Hulshof MC; van Lanschot JJ; Steyerberg EW; van Berge Henegouwen MI; Wijnhoven BP; Richel DJ; Nieuwenhuijzen GA; Hospers GA; Bonenkamp JJ; Cuesta MA; Blaisse RJ; Busch OR; ten Kate FJ; Creemers GJ; Punt CJ; Plukker JT; Verheul HM; Spillenaar Bilgen EJ; van Dekken H; van der Sangen MJ; Rozema T; Biermann K; Beukema JC; Piet AH; van Rij CM; Reinders JG; Tilanus HW; van der Gaast A;
N Engl J Med; 2012 May; 366(22):2074-84. PubMed ID: 22646630
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Shapiro J; van Lanschot JJB; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch ORC; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Bilgen EJS; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A;
Lancet Oncol; 2015 Sep; 16(9):1090-1098. PubMed ID: 26254683
[TBL] [Abstract][Full Text] [Related]
3. [Short-term efficacy and safety of the synchronous neoadjuvant chemoradiotherapy with paclitaxel plus carboplatin in stage III adenocarcinoma of esophagogastric junction].
Ji Y; Peng T; Wang G; Zhang Y; Cao M; Gao Q; Li S
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1019-1024. PubMed ID: 30269322
[TBL] [Abstract][Full Text] [Related]
4. Intensified Neoadjuvant Chemoradiotherapy for Patients with Potentially Resectable Esophageal Cancer: A Retrospective Cohort Study.
Boers J; Joldersma A; van Dalsen AD; Wiegman EM; Schenk BE; de Graaf JC; Pierik EGJM; Timmer PR; de Groot JWB
Ann Surg Oncol; 2020 May; 27(5):1520-1528. PubMed ID: 31828691
[TBL] [Abstract][Full Text] [Related]
5. Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.
Nabavizadeh N; Shukla R; Elliott DA; Mitin T; Vaccaro GM; Dolan JP; Maggiore RJ; Schipper PH; Hunter JG; Thomas CR; Holland JM
Dis Esophagus; 2016 Aug; 29(6):614-20. PubMed ID: 26043837
[TBL] [Abstract][Full Text] [Related]
6. Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial.
Noordman BJ; Verdam MGE; Lagarde SM; Shapiro J; Hulshof MCCM; van Berge Henegouwen MI; Wijnhoven BPL; Nieuwenhuijzen GAP; Bonenkamp JJ; Cuesta MA; Plukker JTM; Spillenaar Bilgen EJ; Steyerberg EW; van der Gaast A; Sprangers MAG; van Lanschot JJB;
Ann Oncol; 2018 Feb; 29(2):445-451. PubMed ID: 29126244
[TBL] [Abstract][Full Text] [Related]
7. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
8. Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.
Anderegg MCJ; van der Sluis PC; Ruurda JP; Gisbertz SS; Hulshof MCCM; van Vulpen M; Mohammed NH; van Laarhoven HWM; Wiezer MJ; Los M; van Berge Henegouwen MI; van Hillegersberg R
Ann Surg Oncol; 2017 Aug; 24(8):2282-2290. PubMed ID: 28424936
[TBL] [Abstract][Full Text] [Related]
9. Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial.
Noordman BJ; Verdam MGE; Lagarde SM; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch OR; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Spillenaar Bilgen EJ; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A; Sprangers MAG; van Lanschot JJB
J Clin Oncol; 2018 Jan; 36(3):268-275. PubMed ID: 29161204
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
11. Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up.
Zemanova M; Petruzelka L; Pazdro A; Kralova D; Smejkal M; Pazdrova G; Honova H
Dis Esophagus; 2010 Feb; 23(2):160-7. PubMed ID: 19515190
[TBL] [Abstract][Full Text] [Related]
12. Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial.
Eyck BM; van Lanschot JJB; Hulshof MCCM; van der Wilk BJ; Shapiro J; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch OR; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Spillenaar Bilgen EJ; van der Sangen MJC; Rozema T; Ten Kate FJW; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A;
J Clin Oncol; 2021 Jun; 39(18):1995-2004. PubMed ID: 33891478
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS).
van Heijl M; van Lanschot JJ; Koppert LB; van Berge Henegouwen MI; Muller K; Steyerberg EW; van Dekken H; Wijnhoven BP; Tilanus HW; Richel DJ; Busch OR; Bartelsman JF; Koning CC; Offerhaus GJ; van der Gaast A
BMC Surg; 2008 Nov; 8():21. PubMed ID: 19036143
[TBL] [Abstract][Full Text] [Related]
14. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
Goense L; van der Sluis PC; van Rossum PSN; van der Horst S; Meijer GJ; Haj Mohammad N; van Vulpen M; Mook S; Ruurda JP; van Hillegersberg R
J Surg Oncol; 2017 Jun; 115(7):812-820. PubMed ID: 28267212
[TBL] [Abstract][Full Text] [Related]
15. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
Ajani JA; Komaki R; Putnam JB; Walsh G; Nesbitt J; Pisters PW; Lynch PM; Vaporciyan A; Smythe R; Lahoti S; Raijman I; Swisher S; Martin FD; Roth JA
Cancer; 2001 Jul; 92(2):279-86. PubMed ID: 11466680
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis.
Li J; Zhao Q; Ge X; Song Y; Tian Y; Wang S; Liu M; Qiao X
BMC Surg; 2021 Mar; 21(1):137. PubMed ID: 33731072
[TBL] [Abstract][Full Text] [Related]
18. Preoperative chemoradiation therapy in combination with panitumumab for patients with resectable esophageal cancer: the PACT study.
Kordes S; van Berge Henegouwen MI; Hulshof MC; Bergman JJ; van der Vliet HJ; Kapiteijn E; van Laarhoven HW; Richel DJ; Klinkenbijl JH; Meijer SL; Wilmink JW
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):190-6. PubMed ID: 25195993
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M;
Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
